Loading
A phase 3 trial of Dalpiciclib in male breast cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.
Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative is a phase 3 interventional study registered as NCT04842617 by Jiangsu HengRui Medicine Co., Ltd., with 5274 participants enrolled, started 2021-04-30 and due to reach its primary completion in 2026-10-31. Interventions recorded: SHR6390, placebo. Conditions listed: Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer. No results are recorded here; the registry entry is the source.
Shares Dalpiciclib, CDK4/6 inhibitors, Jiangsu Hengrui Pharmaceuticals, Small-molecule kinase inhibitors.
Shares Dalpiciclib, CDK4/6 inhibitors, Jiangsu Hengrui Pharmaceuticals.
Shares Jiangsu Hengrui Pharmaceuticals, Small-molecule kinase inhibitors.
Shares Jiangsu Hengrui Pharmaceuticals, Small-molecule kinase inhibitors.
Shares Jiangsu Hengrui Pharmaceuticals, Small-molecule kinase inhibitors.
Shares Jiangsu Hengrui Pharmaceuticals, Small-molecule kinase inhibitors.